Furosemide to lower antenatal severe hypertension (FLASH): a randomized placebo-controlled trial

Maykin, Melanie; Mercer, Elizabeth; Saiki, Kevin; Kaneshiro, Bliss; Miller, Corrie; Tsai, Pai Jong

doi:10.1016/j.ajog.2022.11.925

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, it exhibits diuretic properties, enhancing blood volume, glomerular filtration rate, and prostaglandin production, collectively expediting fluid excretion and reducing intracranial pressure [19]. Furosemide functions by inhibiting the uptake of sodium, potassium, and chloride ions, leading to diuresis and amelioration of cerebral edema, in addition to reducing cerebrospinal fluid production and, consequently, intracranial pressure [20]. Ultimately, our research confirms that integrating surgical procedures with pharmacological therapy significantly reduces postoperative hematoma and edema.…”

Section: Groupsupporting

confidence: 68%

Synergistic effects of neuroendoscopic minimally invasive surgery with mannitol and furosemide in managing hypertensive intracerebral hemorrhage

2024

View full text Add to dashboard Cite

This study aimed to assess the therapeutic efficacy of neuroendoscopic minimally invasive surgery combined with mannitol and furosemide for treating hypertensive intracerebral hemorrhage. We retrospectively analyzed clinical data from 200 patients with hypertensive intracerebral hemorrhage treated at our hospital between July 2020 and July 2022. The patients were categorized into either the experimental group (undergoing neuroendoscopic minimally invasive surgery combined with mannitol and furosemide) or the control group (undergoing neuroendoscopic minimally invasive surgery alone). Then, we compared the efficacy and impact on patients between the two groups. After treatment, the experimental group exhibited a smaller edema area compared to the control group and a reduced hematoma volume (p < 0.001). The total effective rate was significantly higher in the experimental group compared to the control group (p < 0.05). At 7 days post-treatment, patients in the experimental group demonstrated a significantly lower National Institutes of Health Stroke Scale (NIHSS) score compared to the control group (p < 0.001). Additionally, 3 and 7 days after treatment, levels of lipid peroxidation (LPO), neuron-specific enolase (NSE), and S-100β were significantly lower in the experimental group compared to the control group (p < 0.001). Similarly, carotid total blood flow volume (Q) and blood flow velocity (V) were significantly higher in the experimental group at 3 and 7 days post-treatment, with lower peripheral resistance (R) compared to the control group (p < 0.001). The incidence rate of complications was significantly lower in the experimental group compared to the control group (p < 0.05). The integration of neuroendoscopic minimally invasive surgery with mannitol and furosemide administration demonstrates potential in alleviating brain edema, reducing related cytokine levels, facilitating neurological function recovery, and improving cerebral hemodynamic parameters in hypertensive intracerebral hemorrhage patients. These findings merit clinical promotion and application.

show abstract

Section: Groupsupporting

confidence: 68%

Synergistic effects of neuroendoscopic minimally invasive surgery with mannitol and furosemide in managing hypertensive intracerebral hemorrhage

2024

View full text Add to dashboard Cite

show abstract

Furosemide to lower antenatal severe hypertension (FLASH): a randomized placebo-controlled trial

Cited by 1 publication

References 0 publications

Synergistic effects of neuroendoscopic minimally invasive surgery with mannitol and furosemide in managing hypertensive intracerebral hemorrhage

Synergistic effects of neuroendoscopic minimally invasive surgery with mannitol and furosemide in managing hypertensive intracerebral hemorrhage

Contact Info

Product

Resources

About